Institution
Pharmaceutical Product Development
Company•Wilmington, North Carolina, United States•
About: Pharmaceutical Product Development is a company organization based out in Wilmington, North Carolina, United States. It is known for research contribution in the topics: Immunotoxin & Fusion protein. The organization has 402 authors who have published 353 publications receiving 16396 citations.
Topics: Immunotoxin, Fusion protein, Population, Cancer, Antigen
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This paper proposes a Bayesian sequential design with adaptive randomization rates so as to more efficiently attribute newly recruited patients to different treatment arms in 2-arm clinical trials.
Abstract: Bayesian sequential and adaptive randomization designs are gaining popularity in clinical trials thanks to their potentials to reduce the number of required participants and save resources. We propose a Bayesian sequential design with adaptive randomization rates so as to more efficiently attribute newly recruited patients to different treatment arms. In this paper, we consider 2-arm clinical trials. Patients are allocated to the 2 arms with a randomization rate to achieve minimum variance for the test statistic. Algorithms are presented to calculate the optimal randomization rate, critical values, and power for the proposed design. Sensitivity analysis is implemented to check the influence on design by changing the prior distributions. Simulation studies are applied to compare the proposed method and traditional methods in terms of power and actual sample sizes. Simulations show that, when total sample size is fixed, the proposed design can obtain greater power and/or cost smaller actual sample size than the traditional Bayesian sequential design. Finally, we apply the proposed method to a real data set and compare the results with the Bayesian sequential design without adaptive randomization in terms of sample sizes. The proposed method can further reduce required sample size.
1 citations
••
01 Jan 2017TL;DR: What is currently known regarding biomarkers for rheumatoid arthritis is explored and issues to be addressed are discussed as biomarkers are sought for future development programs.
Abstract: Rheumatoid arthritis is a complex systemic autoimmune disease that is characterized by chronic inflammatory polyarthritis, extra-articular features, and autoantibody formation. Although a targeted therapeutic approach using disease-modifying rheumatic drugs has markedly improved overall patient outcomes, there remain significant delays in accomplishing low disease activity in many patients. Reducing the numbers of patients needed for clinical trials is essential to the future of rheumatoid arthritis medical product development programs. Integration of biomarkers into clinical trials for rheumatoid arthritis may be helpful for early disease detection, patient stratification, and treatment response assessment. This goal has not yet been realized but can be achievable with good basic and applied research, systematic data collection, and data systems that can be used to integrate and share data. Herein, we explore what is currently known regarding biomarkers for rheumatoid arthritis and discuss issues to be addressed as biomarkers are sought for future development programs.
1 citations
••
Royal Children's Hospital1, Johns Hopkins University School of Medicine2, University of Mississippi3, Seoul National University4, Catholic University of Korea5, Children's Hospital of Orange County6, Pharmaceutical Product Development7, Children's Hospital of Philadelphia8, Cephalon9, University of Texas Southwestern Medical Center10
TL;DR: This study is a single-arm, phase 1/2 dose-escalating trial to determine the recommended phase 2 dose (RP2D), schedule, pharmacokinetics, and safety profile of bendamustine in pediatric patients with relapsed and refractory acute leukemia.
1 citations
••
TL;DR: This paper expands upon a 1980 proposal by Y. Zurabov to shorten the forwarding time by immediately relaying 406 MHz data from the low earth-orbiting COSPAS/SARSAT satellites to the ground via geostationary satellites, rather than storing the data on-board for delayed transfer, as is presently done.
1 citations
••
Pharmaceutical Product Development1, Cincinnati Children's Hospital Medical Center2, University of North Carolina at Chapel Hill3, Children's Mercy Hospital4, Boston Children's Hospital5, Arnold Palmer Hospital for Children6, Children's Hospital of Wisconsin7, Eli Lilly and Company8, Greenville Health System9, University of Oklahoma10, Baystate Medical Center11, Children's of Alabama12, Great Ormond Street Hospital13, Children's Hospital Oakland14, Memorial Hermann Healthcare System15, University of Michigan16, Genentech17, University of Texas Southwestern Medical Center18, St. Louis Children's Hospital19, Riley Hospital for Children20, Children's Memorial Hospital21, University of Minnesota22, University of Vermont23, Seattle Children's24, Wilmington University25
TL;DR: A quality improvement based approach to data quality monitoring and improvement is feasible and effective in an observational clinical registry to support a Learning Healthcare System.
Abstract: Objective: To implement a quality improvement based system to measure and improve data quality in an observational clinical registry to support a Learning Healthcare System. Data Source: ImproveCareNow Network registry, which as of September 2019 contained data from 314,250 visits of 43,305 pediatric Inflammatory Bowel Disease (IBD) patients at 109 participating care centers. Study Design: The impact of data quality improvement support to care centers was evaluated using statistical process control methodology. Data quality measures were defined, performance feedback of those measures using statistical process control charts was implemented, and reports that identified data items not following data quality checks were developed to enable centers to monitor and improve the quality of their data. Principal Findings: There was a pattern of improvement across measures of data quality. The proportion of visits with complete critical data increased from 72 percent to 82 percent. The percent of registered patients improved from 59 percent to 83 percent. Of three additional measures of data consistency and timeliness, one improved performance from 42 percent to 63 percent. Performance declined on one measure due to changes in network documentation practices and maturation. There was variation among care centers in data quality. Conclusions: A quality improvement based approach to data quality monitoring and improvement is feasible and effective.
1 citations
Authors
Showing all 403 results
Name | H-index | Papers | Citations |
---|---|---|---|
Liangbing Hu | 128 | 480 | 61244 |
Evan A. Stein | 80 | 340 | 36392 |
Steven J. Schwartz | 75 | 313 | 17613 |
Debra A. Schaumberg | 62 | 154 | 15505 |
Lynda A. Szczech | 58 | 175 | 13972 |
Kim L. R. Brouwer | 57 | 247 | 12521 |
Robert S. Wallis | 57 | 147 | 10420 |
Marina A. Dobrovolskaia | 43 | 122 | 10915 |
Al Artaman | 38 | 41 | 61792 |
Bindu Kalesan | 38 | 123 | 8523 |
Stefan Barth | 34 | 238 | 4509 |
Yu.N. Makarov | 32 | 214 | 3578 |
Earl Hubbell | 28 | 76 | 12553 |
Alex Aravanis | 27 | 74 | 5230 |
Izabela Konczak | 24 | 47 | 1770 |